Columbus Regional Healthcare System among First to Offer the HYDROSTM Robotic System, the Next-Generation AI-Powered Platform for Aquablation® Therapy to Treat Benign Prostatic Hyperplasia (BPH) – Enlarged Prostate
AI-Powered Robotic System Now Available at Columbus Regional Healthcare System for Treatment of Enlarged Prostate, Which Impacts Quality of Life for Millions of Men
Whiteville, NC – November 11, 2025-Columbus Regional Healthcare System announces that it is among the first in our region to offer Aquablation® therapy with the new HYDROSTM Robotic System, the next-generation platform to treat men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. Aquablation therapy, now delivered by an AI-powered robotic system, is clinically proven to provide significant, durable BPH symptom relief while preserving sexual function and continence across prostates of all shapes and sizes.
“We performed our first Aquablation procedure at Columbus Regional on November 5th. I hope this patient will be the first of many to receive the benefits and lasting effects of this technology.” said Urologist, Dr. Roc McCarthy, with Advanced Urology-Leland.
BPH is an unfortunate reality of aging for millions of men and impacts urinary function, making it difficult to urinate and fully empty the bladder. Common indicators that a man may be experiencing BPH are the need to urinate immediately or urgently, urinating more often than normal, and urinating frequently at night. Without timely treatment, BPH can lead to severe health issues such as permanent bladder or kidney damage, bladder stones, and incontinence. One in two men ages 51-60 have BPH1, and 99 percent of men say BPH impacts their quality of life. The standard treatment option today is surgery, but this has been shown to impact sexual function and continence.
Aquablation therapy was designed to offer a minimally invasive and effective solution for BPH, minimizing the need for men to choose between safety and efficacy. Aquablation therapy is unique in its use of real-time, ultrasound-guided, robotic-assisted waterjet technology, allowing surgeons to create a personalized treatment plan that precisely targets which prostate tissue to remove and which to preserve. With this tailored approach, the system accurately removes problematic tissue while safeguarding critical anatomy.
The HYDROS Robotic System represents the next evolution in the delivery of Aquablation therapy. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AITM treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience, and deliver a more accurate and consistent treatment plan for better clinical outcomes.
“BPH is a widespread condition that severely compromises quality of life for countless men over age 50. With Aquablation therapy, men can reclaim their lifestyles and find relief from symptoms while preserving sexual function and continence — outcomes that have proven elusive with many traditional treatment modalities,” said Jason Beck, CRHS CEO.
The clinically proven procedure integrates next-generation ultrasound imaging and digital cystoscopy to
provide the surgeon with a multi-dimensional, detailed view of the entire prostate, enabling personalized
treatment planning tailored to each patient’s unique anatomy. Utilizing a heat-free waterjet, the robot
executes the surgeon-defined treatment plan to remove obstructive tissue while protecting critical anatomy. This enables efficient and predictable waterjet resection, standardizing the operative experience across a wide range of prostate sizes and shapes.
Aquablation therapy is backed by 5-year clinical data demonstrating significant durable symptom relief while preserving sexual function and continence across prostates of all shapes and sizes.
For more information on Aquablation therapy, visit aquablation.com or
https://crhealthcare.org/treatments/aquablation-therapy-for-bph-enlarged-prostate/
About Columbus Regional Healthcare System
Founded in 1935, Columbus Regional Healthcare System is a comprehensive healthcare provider serving
southeastern North Carolina. With 154 licensed beds, more than 800 employees, and 50-plus physicians, CRHS is recognized as the region’s first accredited Robotic Center of Excellence and operates the Donayre Cancer Care Center in partnership with Atrium Health Levine Cancer Institute.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing
transformative solutions in urology. Its HYDROSTM Robotic System is the next-generation, AI-powered platform for Aquablation® therapy, a BPH treatment clinically proven to deliver significant, durable symptom relief while preserving sexual function and continence in prostates of all shapes and sizes. The Company has developed a significant and growing body of clinical evidence, including numerous clinical studies and peer-reviewed publications, that support the benefits and clinical advantages of Aquablation therapy.
- Roehrborn, CG, Rosen, RC. Medical therapy options for aging men with benign prostatic hyperplasia: focus
on alfuzosin 10 mg once daily. Clinical Interventions in Aging 2008:3(3). - Data on file at PROCEPT BioRobotics.
Risk and Safety Information
All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a
number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam® Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required. As with any surgical urologic procedure, potential perioperative risks of the Aquablation procedure include but are not limited to the following, some of which may lead to serious outcomes and may require intervention: Anesthesia risk, Bladder or prostate capsule perforation, Bladder neck contracture, Bleeding or blood in the urine, Bruising, Penile or pelvic pain, Irritative symptoms, which may include dysuria, urgency or frequency, Infection, Transurethral resection (TUR) syndrome, Electric shock/burn, Urethral damage causing false passage or stricture, Rectal incontinence/perforation, Sexual dysfunction, including ejaculatory and erectile dysfunction, Incontinence or overactive bladder, Embolism, Urinary Retention.
Rx Only
Please review the Instructions for Use and any accompanying documentation for a complete listing of
indications, contraindications, warnings, precautions, and potential adverse events.
© 2024 PROCEPT BioRobotics Corporation. All rights reserved. AQUABLATION, HYDROS, PROCEPT
BioRobotics, and the PROCEPT BioRobotics logo are trademarks and/or registered trademarks of PROCEPT BioRobotics Corporation. ML0636.A
